Type 1 DiabetesNCT07097818
Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2
A study testing T1D team, structured education, peer support , and diabetes technologies and Routine Management in people with Type 1 Diabetes, run by Second Xiangya Hospital of Central South University at 10 sites in China.
Trial summary
The GLITTER Study 2 is a cluster randomized trial that will evaluate the impact of comprehensive and intensive management, comprising a team, technology, education, and peer resources, on metabolic control and psychological outcomes in patients with type 1 diabetes. Read more about this study
- Who is it for?
- Ages 6 years and older
- Conditions the study is for
- Type 1 Diabetes
- What is being tested?
- T1D team, structured education, peer support , and diabetes technologies and Routine Management
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 400 participants
- Where
- 10 sitesChina
- Study dates
- 18 Aug 2025to 1 Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- Patients who plan to receive diabetes treatment at other hospitals.
- Patients who have used an automated insulin delivery system or sensor-augmented pump within 3 months prior to screening.
- Patients who refuse to use continuous glucose monitoring or insulin pumps, or refuse data upload and remote monitoring.
- Patients with severe cardiovascular, cerebrovascular, hepatic, or renal diseases; uncontrolled systemic diseases, thyroid diseases; autoimmune diseases; or malignancies.
- Patients diagnosed with hematologic or bleeding disorders.
- Patients who have received red blood cell transfusions or erythropoiesis-stimulating agents within 3 months prior to screening.
Show all 15Show fewer
- Patients who have used any oral, injectable, or intravenous corticosteroids within 8 weeks prior to screening, or who plan to use corticosteroids during the trial.
- Patients with severe skin diseases that may affect the application sites of continuous glucose monitoring or insulin pump patches.
- Patients with auditory or visual impairments.
- Patients with alcohol or drug abuse.
- Patients who plan to receive blood transfusions during the study period.
- Patients who plan to undergo elective surgery requiring general anesthesia or dialysis during the study period.
- Pregnant women, women planning to become pregnant within 1 year of the study, or women who are breastfeeding.
- Patients who are currently participating in or have participated in other drug or device trials within the last 2 weeks.
- Patients who, in the investigator's opinion, are not suitable for participation in this clinical trial, such as those with a history of vision impairment, eating disorders, celiac disease, etc.
Trial locations and contacts
10 sites in 1 country. Contact the study team or a site near you to ask about taking part.
10 sites in 1 country
China10 sites, 10 recruiting
- Not yet recruiting
Department of Endocrinology and Metabolism, Peking University People's Hospital
Beijing, Beijing Municipality
Xiaoling Cai, dr_junel@sina.com
- Recruiting
Institute of Metabolism and Endocrinology, Second Xiangya Hospital of Centra South University
Changsha, Hunan, 410011
Xia Li, MD, PhD, +86 13974885753, lixia2014@vip.163.com
- Not yet recruiting
Department of Endocrinology and Metabolism, Laboratory of Diabetes and metabolism research, West China Hospital, Sichuan University
Chengdu, Sichuan
Nanwei Tong, tongnw@scu.edu.cn
- Not yet recruiting
Department of Endocrinology, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health
Hangzhou, Zhejiang
Junfen Fu, fjf68@zju.edu.cn
- Recruiting
Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
Luoyang, Henan, 471003
Hongwei Jiang, jianghw@haust.edu.cn
- Not yet recruiting
Department of Endocrinology, Quanzhou First Hospital Affiliated to Fujian Medical University
Quanzhou, Fujian
Yi Zhang, zhangyi135@qzdyyy.com
- Not yet recruiting
Department of Endocrinology and Metabolism, Institute of Endocrinology, The First Affiliated Hospital of China Medical University
Shenyang, Liaoning
Yanli Cao, vanilla421@163.com
- Not yet recruiting
Department of Endocrinology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University
Shenzhen, Guangdong
Haiyan Li, haiyanli78@163.com
- Not yet recruiting
Second Department of Endocrinology and Metabolism, Tangshan Gongren Hospital
Tangshan, Hebei
Hui Fang, fanghui2818@126.com
- Not yet recruiting
Department of Endocrinology, Zhongnan Hospital of Wuhan University
Wuhan, Hubei
Zhe Dai, daizhe@znhospital.cn
About this study
Official title: Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2: a Multicentre, Cluster-randomized, Controlled Trial
The GLITTER Study 2 is a cluster randomized trial that will evaluate the impact of comprehensive and intensive management, comprising a team, technology, education, and peer resources, on metabolic control and psychological outcomes in patients with type 1 diabetes.
Read the detailed description
Type 1 diabetes (T1D) is a lifelong metabolic disease with an increasing disease burden. Despite continuous advancements in diagnostic and treatment technologies, patients of all age groups fail to meet the glycemic targets. Currently, there is a common deficiency in the management of T1D both domestically and internationally, which is specifically manifested as: the disconnection between blood glucose monitoring and insulin adjustment, low utilization rate of new technologies, insufficient patient self-management training, and the absence of psychological intervention, etc.
This GLITTER Study 2 extends the GLITTER Study (Glycemic Improvement with Team, Technology, Education and Peer Resources in type 1 diabetes) by implementing its philosophy (Team, Technology, Education, Peer Resources) to develop a comprehensive T1D management model, integrating these components to enhance management and evaluate effectiveness.
This multicentre, cluster-randomized controlled trial will be conducted across 10 hospitals. It aims to enroll patients with T1D aged ≥6 years who have had the disease for >3 months. Five hospitals were randomly assigned to the comprehensive management intervention group, and five to the usual care group. A total of 400 individuals were recruited into the study. The intervention for the intervention group includes: T1D team (dedicated T1D physicians, certified diabetes educators, registered dietitians), centralized structured education (courses, short videos, and structured educational materials), peer support (volunteer matching, camp, volunteer peer live streaming), and diabetes technologies (insulin pumps and continuous glucose monitoring). The control group received usual care, with the five assigned hospitals continuing their clinical practice. This 52-week trial includes assessments at the following timepoints: screening, week 13 (visit 2), week 26 (visit 3), week 39 (visit 4), and week 52 (visit 5). Throughout the study period, we will evaluate the model's impact on glycemic control and psychosocial outcomes, aiming to establish an evidence-based clinical practice paradigm for T1D management.
- Conditions
- Type 1 Diabetes
- Being tested
- T1D team, structured education, peer support , and diabetes technologies, Routine Management
- Keywords
- Type 1 diabetes, Comprehensive management, T1D teams, Structured education, Peer resources, Diabetes technologies, Glycemic control
- Medical subject headings
- Diabetes Mellitus, Type 1
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
T1D team, structured education, peer support , and diabetes technologiesBehavioural
Patients with T1D will use insulin pumps and CGM , while undergoing structured education courses under the management of a specialized T1D team and engaging in peer support activities.
Routine ManagementBehavioural
Patients with T1D will be managed according to the routine diagnosis and education model of each hospital.
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Experimental | Patients with T1D in the intervention group will undergo comprehensive management. Receives: Behavioral: T1D team, structured education, peer support , and diabetes technologies |
| Control group | Other | Patients with T1D in the control group will receive routine management. Receives: Behavioral: Routine Management |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in HbA1c
The primary outcome is the Change in Glycated Hemoglobin A1C (HbA1c) before and after the 52 weeks intervention. HbA1c is a physiological marker of the percentage of red blood cells that have glycated (bonded with a sugar). HbA1c is used to measure changes in average blood sugar over the past three months.
Measured: Baseline, 13, 26, and 52 weeks
Secondary outcomes (23)
Percentage of patients in each group with HbA1c <7.0%
HbA1c serves as a crucial physiological marker for assessing average blood sugar levels over the preceding three months. Values below 7.0 are deemed optimal for long-term health. Consequently, a higher number or percentage of individuals achieving an HbA1c level below 7.0 is indicative of a positive outcome, reflecting better glycemic control and reduced risk of complications.
Measured: 52 weeks
Percentage of patients in each group with HbA1c <7.5%
HbA1c serves as a crucial physiological marker for assessing average blood sugar levels over the preceding three months. Values below 7.5 are deemed optimal for long-term health. Consequently, a higher number or percentage of individuals achieving an HbA1c level below 7.5 is indicative of a positive outcome, reflecting better glycemic control and reduced risk of complications.
Measured: 52 weeks
CGM-measured Percentage Time 70-180 mg/dL (3.9-10.0 mmol/L)
The CGM-measured percentage time 70-180 mg/dL (3.9-10.0 mmol/L) refers to the proportion of time during which an individual's blood glucose levels, as continuously monitored by a CGM device. This metric is crucial for assessing glycemic control in individuals with diabetes. Maintaining blood glucose within this target range is associated with better health outcomes and reduced risk of complications.
Measured: Baseline, 13, 26, and 52 weeks
CGM-measured Percentage Time >180 mg/dL (>10.0 mmol/L)
Smaller percentages of CGM-measured time above 180 mg/dL is considered a positive outcome.
Measured: Baseline, 13, 26, and 52 weeks
CGM-measured Percentage Time >250 mg/dL (>13.9 mmol/L)
CGM measured blood sugar values above 250 mg/dL are considered to be undesirable. Thus, less time spent above 250mg/dL is considered a positive outcome.
Measured: Baseline, 13, 26, and 52 weeks
CGM-Measured Percentage Time <70 mg/dL (<3.9 mmol/L)
Blood sugar values measured by CGM that fall below 70 mg/dL are considered potentially hazardous, as they may lead to unconsciousness and, in severe cases, even death. Therefore, minimizing the time spent below 70 mg/dL is regarded as a highly positive outcome, reflecting better management of low blood sugar episodes and enhanced safety for the individual.
Measured: Baseline, 13, 26, and 52 weeks
CGM-Measured Percentage Time <60 mg/dL (<3.3 mmol/L)
Blood sugar values measured by CGM that fall below 60 mg/dL are considered potentially hazardous, as they may lead to unconsciousness and, in severe cases, even death. Therefore, minimizing the time spent below 60 mg/dL is regarded as a highly positive outcome, reflecting better management of low blood sugar episodes and enhanced safety for the individual.
Measured: Baseline, 13, 26, and 52 weeks
CGM-measured Glucose Standard Deviation (SD)
Standard Deviation represents how much glucose levels fluctuate over time from a given average.
Measured: Baseline, 13, 26, and 52 weeks
CGM-Measured Glucose Coefficient of Variation
The Coefficient of Variability (CV) is calculated as the ratio of the standard deviation to the mean of blood sugar values for each participant, as measured by CGM. The reported CV value is derived by multiplying the ratio of the standard deviation to the mean by 100, providing a percentage that reflects the degree of variability in blood sugar levels across the population. A higher CV value, which can range up to 100, signifies greater dispersion of CGM values, indicating more significant fluctuations in blood sugar levels. This increased variability is generally considered an unfavorable outcome, as it may suggest less stable glucose control. Conversely, the minimum CV value is 0, which would indicate no variability in blood sugar levels, representing perfect stability.
Measured: Baseline, 13, 26, and 52 weeks
CGM-Measured Glucose Risk Index (GRI)
The CGM-Measured Glucose Risk Index (GRI) is a comprehensive metric derived from CGM data, designed to quantify the overall risk associated with blood glucose variability. It integrates multiple aspects of glucose levels, including the frequency and severity of both hypo- and hyperglycemic events, as well as the duration of time spent outside the target glucose range. A lower GRI score indicates better glucose stability and lower risk of adverse outcomes related to blood sugar fluctuations.
Measured: Baseline, 13, 26, and 52 weeks
Self-Management of Type 1 Diabetes for Chinese Adults
The Self-Management of Type 1 Diabetes for Chinese Adults (SMOD-CA) scale is a validated instrument specifically designed to assess the self-management behaviors and capabilities of adults with type 1 diabetes in the Chinese population. The SMOD-CA consists of 30 items. Responses are rated on a five-point scale, with higher scores indicating better self-management ability. The total score ranges from 0 to 120.
Measured: Baseline and 52 weeks
23-item Chinese Version of Self-Report Measure of Self-Management of Type 1 Diabetes for Adolescents
The 23-item Chinese Version of Self-Report Measure of Self-Management of Type 1 Diabetes for Adolescents (C-SMOD-A-23) is a validated and simplified instrument designed to assess the self-management behaviors and capabilities of adolescents with type 1 diabetes.
Measured: Baseline and 52 weeks
Assessment of sleep quality: Pittsburgh Sleep Quality Index
Pittsburgh Sleep Quality Index (PSQI), a self-report questionnaire comprising seven component scores (subjective sleep quality, sleep latency, duration of sleep, sleep efficiency habits, sleep disturbances, use of sleeping medication, and daytime dysfunction), is used to evaluate sleep quality over the last month.
Measured: Baseline and 52 weeks
Hypoglycemic Fear Scale
The Hypoglycemic Fear Scale is a widely used and validated assessment tool designed to measure the level of fear and anxiety that individuals with diabetes, particularly those with type 1 diabetes, experience in relation to hypoglycemia (low blood sugar).
Measured: Baseline and 52 weeks
Diabetes Technology Attitude Scale
The Diabetes Technology Attitude Scale is a specialized assessment tool designed to evaluate individuals' attitudes toward diabetes-related technologies.
Tool lists statement and participants reports how much they agree with the statement.
Measured: Baseline and 52 weeks
Barriers to Technology
The Barriers to Technology Questionnaire typically consists of several key sections, each designed to capture different aspects of technology adoption and use.
Measured: Baseline and 52 weeks
Diabetes Treatment Satisfaction Questionnaire
The Diabetes Treatment Satisfaction Questionnaire (DTSQ) is a comprehensive and widely utilized tool designed to assess the level of satisfaction that individuals with diabetes have with their current treatment regimens. The DTSQ is usually administered as a self-report questionnaire, allowing patients to rate their responses on a Likert scale, typically ranging from "very dissatisfied" to "very satisfied." The total score is calculated by summing the responses to all relevant items, with higher scores indicating greater satisfaction with the treatment.
Measured: Baseline and 52 weeks
Diagnosis and measurement of the severity of depression: Patient Health Questionnaire
The Patient Health Questionnaire (PHQ-9) will be used to assess depressive symptoms, including suicidal ideation, over the last two weeks (9 questions). Items are scored 0-3, resulting in a total score of 0-27. Higher scores indicate more symptoms of depression.
Measured: Baseline and 52 weeks
Depression Self-Rating Scale for Children
The Depression Self-Rating Scale for Children (DSRSC) is a standardized psychological assessment tool designed to measure depressive symptoms in children and adolescents. This self-report inventory allows young individuals to rate the frequency and severity of various depressive feelings and behaviors they may be experiencing.
Measured: Baseline and 52 weeks
Generalized Anxiety Disorder 7-item scale
The Generalized Anxiety Disorder 7-item scale (GAD-7) consists of seven items. Each item asks respondents to rate how often they have been bothered by specific anxiety-related symptoms over the past two weeks.
Measured: Baseline and 52 weeks
WHO-5 Well-Being Index
The WHO-5 Well-Being Index (WHO-5) is a brief, self-report questionnaire designed to assess subjective well-being. The WHO-5 consists of five simple and straightforward items. Each item is rated on a 6-point Likert scale, ranging from 0 (not present) to 5 (constantly present). The total score is calculated by summing the responses to all five items, resulting in a score that ranges from 0 to 25. Higher scores indicate better well-being.
Measured: Baseline and 52 weeks
Evaluation of the perception of hypoglycemia in the population tested with Clarke score
Clarke Hypoglycemia Awareness Scores (0-7 score with higher scores associated with impaired awareness).
Measured: Baseline and 52 weeks
Evaluation of the perception of hypoglycemia in the population tested with Gold score
The Gold method is used to assess impaired awareness of hypoglycemia. The scale is from 1 to 7. A score of 4 or more indicates impaired awareness of hypoglycemia.
Measured: Baseline and 52 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2025
- Study start18 Aug 2025
- Primary completion1 Mar 2027 (estimated)
- Study completion1 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 1 DiabetesStudies of the same condition, open and under way.
- More trials run by Second Xiangya Hospital of Central South UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xia Li, Second Xiangya Hospital of Central South University
- Investigators
- Xia Li, MD, PhD, Principal investigator, Second Xiangya Hospital of Central South University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07097818
- Sponsor's protocol ID
- KYZ20250019
- Status last verified
- Jul 2025
- First submitted
- 24 Jul 2025
- Last updated
- 3 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2: a Multicentre, Cluster-randomized, Controlled Trial
- ClinicalTrials.gov ID
- NCT07097818
- Acronym / sponsor ID
- KYZ20250019
- Conditions
- Type 1 Diabetes
- Keywords
- Type 1 diabetes, Comprehensive management, T1D teams, Structured education, Peer resources, Diabetes technologies, Glycemic control
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Second Xiangya Hospital of Central South UniversityUniversity, hospital or other
- Study start
- 18 Aug 2025 (actual)
- Primary completion
- 1 Mar 2027 (estimated)
- Study completion
- 1 Apr 2027 (estimated)
- First posted
- 31 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The GLITTER Study 2 is a cluster randomized trial that will evaluate the impact of comprehensive and intensive management, comprising a team, technology, education, and peer resources, on metabolic control and psychological outcomes in patients with type 1 diabetes.
Detailed description
Type 1 diabetes (T1D) is a lifelong metabolic disease with an increasing disease burden. Despite continuous advancements in diagnostic and treatment technologies, patients of all age groups fail to meet the glycemic targets. Currently, there is a common deficiency in the management of T1D both domestically and internationally, which is specifically manifested as: the disconnection between blood glucose monitoring and insulin adjustment, low utilization rate of new technologies, insufficient patient self-management training, and the absence of psychological intervention, etc.
This GLITTER Study 2 extends the GLITTER Study (Glycemic Improvement with Team, Technology, Education and Peer Resources in type 1 diabetes) by implementing its philosophy (Team, Technology, Education, Peer Resources) to develop a comprehensive T1D management model, integrating these components to enhance management and evaluate effectiveness.
This multicentre, cluster-randomized controlled trial will be conducted across 10 hospitals. It aims to enroll patients with T1D aged ≥6 years who have had the disease for >3 months. Five hospitals were randomly assigned to the comprehensive management intervention group, and five to the usual care group. A total of 400 individuals were recruited into the study. The intervention for the intervention group includes: T1D team (dedicated T1D physicians, certified diabetes educators, registered dietitians), centralized structured education (courses, short videos, and structured educational materials), peer support (volunteer matching, camp, volunteer peer live streaming), and diabetes technologies (insulin pumps and continuous glucose monitoring). The control group received usual care, with the five assigned hospitals continuing their clinical practice. This 52-week trial includes assessments at the following timepoints: screening, week 13 (visit 2), week 26 (visit 3), week 39 (visit 4), and week 52 (visit 5). Throughout the study period, we will evaluate the model's impact on glycemic control and psychosocial outcomes, aiming to establish an evidence-based clinical practice paradigm for T1D management.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention group | Experimental | Behavioral: T1D team, structured education, peer support , and diabetes technologiesPatients with T1D in the intervention group will undergo comprehensive management. |
| Control group | Other | Behavioral: Routine ManagementPatients with T1D in the control group will receive routine management. |
Who may qualify
- Ages
- 6 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (15 listed)
- Patients who plan to receive diabetes treatment at other hospitals.
- Patients who have used an automated insulin delivery system or sensor-augmented pump within 3 months prior to screening.
- Patients who refuse to use continuous glucose monitoring or insulin pumps, or refuse data upload and remote monitoring.
- Patients with severe cardiovascular, cerebrovascular, hepatic, or renal diseases; uncontrolled systemic diseases, thyroid diseases; autoimmune diseases; or malignancies.
- Patients diagnosed with hematologic or bleeding disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| T1D team, structured education, peer support , and diabetes technologiesPatients with T1D will use insulin pumps and CGM , while undergoing structured education courses under the management of a specialized T1D team and engaging in peer support activities. | Behavioural | Intervention group |
| Routine ManagementPatients with T1D will be managed according to the routine diagnosis and education model of each hospital. | Behavioural | Control group |
Primary outcome
Change in HbA1c
Time frame: Baseline, 13, 26, and 52 weeks
The primary outcome is the Change in Glycated Hemoglobin A1C (HbA1c) before and after the 52 weeks intervention. HbA1c is a physiological marker of the percentage of red blood cells that have glycated (bonded with a sugar). HbA1c is used to measure changes in average blood sugar over the past three months.
23 secondary outcomes
Percentage of patients in each group with HbA1c <7.0%
Time frame: 52 weeks
Percentage of patients in each group with HbA1c <7.5%
Time frame: 52 weeks
CGM-measured Percentage Time 70-180 mg/dL (3.9-10.0 mmol/L)
Time frame: Baseline, 13, 26, and 52 weeks
CGM-measured Percentage Time >180 mg/dL (>10.0 mmol/L)
Time frame: Baseline, 13, 26, and 52 weeks
CGM-measured Percentage Time >250 mg/dL (>13.9 mmol/L)
Time frame: Baseline, 13, 26, and 52 weeks
CGM-Measured Percentage Time <70 mg/dL (<3.9 mmol/L)
Time frame: Baseline, 13, 26, and 52 weeks
CGM-Measured Percentage Time <60 mg/dL (<3.3 mmol/L)
Time frame: Baseline, 13, 26, and 52 weeks
CGM-measured Glucose Standard Deviation (SD)
Time frame: Baseline, 13, 26, and 52 weeks
CGM-Measured Glucose Coefficient of Variation
Time frame: Baseline, 13, 26, and 52 weeks
CGM-Measured Glucose Risk Index (GRI)
Time frame: Baseline, 13, 26, and 52 weeks
Self-Management of Type 1 Diabetes for Chinese Adults
Time frame: Baseline and 52 weeks
23-item Chinese Version of Self-Report Measure of Self-Management of Type 1 Diabetes for Adolescents
Time frame: Baseline and 52 weeks
Assessment of sleep quality: Pittsburgh Sleep Quality Index
Time frame: Baseline and 52 weeks
Hypoglycemic Fear Scale
Time frame: Baseline and 52 weeks
Diabetes Technology Attitude Scale
Time frame: Baseline and 52 weeks
Barriers to Technology
Time frame: Baseline and 52 weeks
Diabetes Treatment Satisfaction Questionnaire
Time frame: Baseline and 52 weeks
Diagnosis and measurement of the severity of depression: Patient Health Questionnaire
Time frame: Baseline and 52 weeks
Depression Self-Rating Scale for Children
Time frame: Baseline and 52 weeks
Generalized Anxiety Disorder 7-item scale
Time frame: Baseline and 52 weeks
WHO-5 Well-Being Index
Time frame: Baseline and 52 weeks
Evaluation of the perception of hypoglycemia in the population tested with Clarke score
Time frame: Baseline and 52 weeks
Evaluation of the perception of hypoglycemia in the population tested with Gold score
Time frame: Baseline and 52 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Type 1 Diabetes
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
RecruitingPhase 1
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Melanoma
Active, not recruitingPhase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Xia Li, MD, PhD principal investigator
Second Xiangya Hospital of Central South University
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing T1D team, structured education, peer support , and diabetes technologies and Routine Management in people with Type 1 Diabetes, run by Second Xiangya Hospital of Central South University at 10 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xia Li (+86 13974885753, lixia2014@vip.163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in HbA1c (time frame: Baseline, 13, 26, and 52 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2025.